Taylor & Francis

Targeted searches across Retraction Watch, X, and web sources up to March 19, 2026, reveal no new large-scale retraction batches, papermill operations, or systemic fraud in scientific publications. Isolated incidents include Elsevier retracting six papers from an energy-technology journal due to unauthorized author changes and fictitious emails [web:10], University of Melbourne launching a formal investigation into education researcher John Hattie [post:5], and mass resignation of editors at Communications in Algebra over review processes and EIC removal [post:9][web:11]. Known cases such as Heliyon batches, Hitler Louis retractions (stable at ~35), Purdue suspension, and ORI's Chen-Yeh Ke finding show no updates [web:23][web:33][web:16].

Searches through March 18, 2026, confirm additional PubPeer-prompted retractions in lung cancer-related papers, including a notice for Long noncoding RNA FAM201A mediating metastasis and a Sage journal retraction for in vitro assays in human lung cancer cells, but these appear as figure concerns rather than confirmed fraud. No developments on ongoing high-profile cases such as OIST's response to Paola Laurino's flagged papers, Sonia Melo's MD Anderson lawsuit, or Taylor & Francis investigation of the Rose/McKernan/Speicher Autoimmunity Reviews paper. PubPeer flags on 2026 Nature Medicine lung cancer trial and Cancer Discovery papers persist without resolutions, while Retraction Watch reports remain focused on non-biomedical issues.